Summary: In patients with type 2 diabetes mellitus (T2DM), Ebenatide treatment significantly improved glycemic control (HbA1c), time in range (TIR), triglyceride-glucose index (TyG), weight, and waist-to-height ratio (WHtR) compared to baseline measures, though it was associated with minimal side effects such as mild gastrointestinal symptoms. PICO Description Population Adults with type 2 diabetes mellitus (T2DM). Intervention Ebenatide treatment for 24 weeks, sustained for at least 52 weeks, targeting glycemic and metabolic improvement. Comparison Baseline glycemic and metabolic measures prior to Ebenatide treatment. Outcome Ebenatide significantly reduced HbA1c and improved glycemic metrics (TIR, TyG). It also lowered body weight and reduced…
Author: FWA
Summary: In adults with obesity participating in a double-blind clinical pharmacology study, once-daily oral semaglutide (dose-escalated to 50 mg over 20 weeks) significantly reduced energy intake by 39.2%, decreased body weight by 9.8%, and improved appetite control compared to placebo administered over the same 20-week period, though it was associated with no significant effect on gastric emptying. PICO Description Population Adults with obesity (n=61) who participated in a clinical pharmacology, double-blind study. Intervention Once-daily oral semaglutide (dose-escalated to 50 mg over 20 weeks). Comparison Placebo treatment administered for the same 20-week period. Outcome Semaglutide significantly reduced energy intake by -39.2%…
Summary: In adults with obesity-related heart failure with preserved ejection fraction (HFpEF), left ventricular ejection fraction ≥45%, and BMI ≥30 kg/m², weekly semaglutide 2.4 mg for 52 weeks significantly improved HFpEF symptoms, physical limitations, and exercise capacity, with weight loss more pronounced in women (-9.6%) than men (-7.2%) compared to matched placebo with standard care, though it was associated with fewer serious adverse events than placebo. PICO Description Population Adults with obesity-related heart failure with preserved ejection fraction (HFpEF), left ventricular ejection fraction ≥45%, and body mass index (BMI) ≥30 kg/m², including both male and female participants, assessed for sex-specific…
Summary: In people with chronic breathlessness and Chronic Obstructive Pulmonary Disease (COPD), regular low-dose morphine significantly improved diurnal cortisol slope and reduced subjective breathlessness compared to no morphine intervention, though it was associated with minor gastrointestinal side effects. PICO Description Population People with chronic breathlessness and Chronic Obstructive Pulmonary Disease (COPD). Intervention Regular low-dose morphine (dosage not specified in the summary). Comparison Control group with no morphine intervention. Outcome Low-dose morphine resulted in significant improvement of diurnal cortisol slope (steeper slope) and reduced subjective breathlessness. Minor gastrointestinal side effects were noted but were manageable in clinical settings. Source: Diana…
Summary: In participants with prediabetes and type 2 diabetes, circulating Gremlin 2 (Grem2) levels significantly decreased and were associated with impaired β-cell function compared to those with normal glucose tolerance, though it was associated with partial restoration through antidiabetic interventions. PICO Description Population Participants with prediabetes and type 2 diabetes (T2D), compared to those with normal glucose tolerance. Intervention Measurement of circulating Gremlin 2 (Grem2) levels and its modulation through antidiabetic interventions. Comparison Comparison of circulating Grem2 levels between participants with normal glucose tolerance, prediabetes, and T2D. Outcome Reduced circulating Grem2 levels were associated with impaired β-cell function in…
Summary: In patients with obesity-related heart failure with preserved ejection fraction (HFpEF), including those enrolled in the STEP-HFpEF and STEP-HFpEF DM trials, semaglutide 2.4 mg weekly significantly reduced NT-proBNP levels (estimated treatment ratio: 0.82; 95% CI: 0.74–0.91; P = 0.0002), improved health status, and promoted weight loss compared to placebo under identical trial conditions, though it was associated with no significant adverse effects across NT-proBNP baseline tertiles. PICO Description Population Patients with obesity-related heart failure with preserved ejection fraction (HFpEF), enrolled in the STEP-HFpEF and STEP-HFpEF DM trials; total of 1,145 participants. Intervention Administration of semaglutide 2.4 mg weekly to…
Summary: In patients with polycystic ovary syndrome (PCOS), Salvia officinalis extract significantly reduced triglyceride levels and oxidative stress markers compared to placebo, though it was associated with no significant changes in other lipid profile markers. PICO Description Population Patients diagnosed with polycystic ovary syndrome (PCOS). Intervention Salvia officinalis extract (dosages as prescribed by study protocol). Comparison Placebo capsules administered to the control group. Outcome Salvia officinalis extract significantly decreased triglyceride levels and oxidative stress markers. However, no significant changes in other lipid profile markers were observed. These findings suggest its potential as an adjunctive therapy for metabolic and oxidative imbalances…
Brief Results In Adults with hypoparathyroidism, TransCon PTH (palopegteriparatide) administered once daily compared to Placebo showed At week 52, 81% achieved normal serum calcium and independence from conventional therapy, 95% achieved independence from conventional therapy, mean 24-hour urine calcium decreased from 376 mg/day to 195 mg/day, most adverse events were mild or moderate. Study Details Population Adults with hypoparathyroidism Intervention TransCon PTH (palopegteriparatide) administered once daily Comparison Placebo Outcome At week 52, 81% achieved normal serum calcium and independence from conventional therapy, 95% achieved independence from conventional therapy, mean 24-hour urine calcium decreased from 376 mg/day to 195 mg/day, most…
Summary: In Chinese adults with type 2 diabetes (T2D), low-calorie diet interventions (LCFD and LCRFD) significantly achieved comparable rates of T2D remission and weight loss compared to other populations undergoing similar interventions, though they were associated with variability in individual responses. PICO Description Population Chinese adults with type 2 diabetes (T2D). Intervention Low-calorie diet (LCFD and LCRFD—low-calorie with reduced fat diet). Comparison T2D remission rates and weight loss outcomes in other populations following similar low-calorie diets. Outcome Low-calorie diets achieved similar rates of T2D remission and weight loss. Notable variability in individual responses was observed. The study highlights that dietary…
Brief Results In Adults with chronic kidney disease (eGFR ≥25 ml min-1 1.73 m-2 and UACR ≥30 and <3,500 mg g-1) and overweight or obesity (BMI ≥27 kg m-2) without diabetes, Semaglutide 2.4 mg per week for 24 weeks compared to Placebo for 24 weeks showed Semaglutide treatment reduced UACR by -52.1% (95% CI -65.5, -33.4; p < 0.0001) compared to placebo. Study Details Population Adults with chronic kidney disease (eGFR ≥25 ml min-1 1.73 m-2 and UACR ≥30 and <3,500 mg g-1) and overweight or obesity (BMI ≥27 kg m-2) without diabetes Intervention Semaglutide 2.4 mg per week for…